Maternal exposure to the antidepressant fluoxetine impairs sexual motivation in adult male mice

Gouvêa, Thiago S.; Morimoto, Helena Kaminami; Faria, Maria José Sparça Salles de; Moreira, Estefânia Gastaldello; Gerardin, Daniela Cristina Ceccatto

doi:10.1016/j.pbb.2008.03.025

Cited by 46 publications

(31 citation statements)

References 32 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Conversely, two studies found that perinatal SSRIs increased weight at the juvenile stage [84] and adulthood [52], while other studies have failed to find a difference in weight in offspring at pre-weaning [86], at adulthood [84], from pre-weaning into the juvenile stage [13,18,54,56], and from pre-weaning into adulthood [16,52,59,88]. In terms of other types of animal studies, gestational SSRIs in sheep reduced weight of lambs at P2 and P3, but with no difference at P5 [60].…”

Section: Animal Studiesmentioning

confidence: 99%

Perinatal selective serotonin reuptake inhibitor (SSRI) effects on body weight at birth and beyond: A review of animal and human studies

Hutchison

Mâsse

Pawluski

et al. 2018

Reproductive Toxicology

View full text Add to dashboard Cite

. Perinatal selective serotonin reuptake inhibitor (SSRI) effects on body weight at birth and beyond A review of animal and human studies. Reproductive Toxicology, Elsevier, 2018, 77, pp.109-121. 10 Highlights  Our paper reviews our current understanding of the impact of prenatal SSRI exposure on weight and growth using both human and animal findings.  Our review extends the previously published review paper by Grzeskowiak and colleagues in Repro Tox in 2012 by including findings beyond infancy, the impact of maternal mood -pre and post natal, and given that the majority our 5HT is in the gastrointestinal (GI) system we speculate that altering 5HT signaling, via SSRI exposure might have an impact on GI function and later weight gain.  With recent advances in our understanding of the gut-brain axis and the role of 5HT, we raise critical questions about how weight and growth outcomes might be related to SSRI induced changes in the GI microbiome.  Our paper provides an updated review of the literature (e.g., Leuner et al 2014;Nezvalová-Henriksen et al., 2016), with a particular focus on weight related outcomes beyond birth, developmental aspects of SSRI exposure that might also impact weight and growth, as well as provides detailed suggestions for future research. AbstractThe long-term impact of selective serotonin reuptake inhibitor (SSRI) antidepressant treatment during pregnancy and postpartum on offspring outcomes is still not clear. Specifically, perinatal SSRI exposure may have long-term consequences for body weight and related health outcomes in the newborn period and beyond. This review focuses on the impact of perinatal SSRI exposure on weight using human and animal findings. The impact of maternal mood is also explored. We propose potential mechanisms for weight changes, including how early alterations in serotonin signaling may have implications for weight via changes in metabolism and motor development.As the majority of serotonin is in the gastrointestinal (GI) system we also speculate that perinatal SSRI exposure might alter the brain-gut relationship, via the microbiome, leading to changes in feeding behavior and weight.

show abstract

Section: Animal Studiesmentioning

confidence: 99%

Perinatal selective serotonin reuptake inhibitor (SSRI) effects on body weight at birth and beyond: A review of animal and human studies

Hutchison

Mâsse

Pawluski

et al. 2018

Reproductive Toxicology

View full text Add to dashboard Cite

show abstract

“…Prenatal fluoxetine exposure produced impaired sexual motivation in adult mice measured by no difference in preference for social contact with a male versus a female (Gouvêa et al, 2008). Aggressive behavior and foot shock-induced aggressive behavior have been shown to increase following prenatal SSRI exposure (Singh et al, 1998;Coleman et al, 1999).…”

Section: H Behavioral Outcomesmentioning

confidence: 99%

Prenatal Antidepressant Exposure: Clinical and Preclinical Findings

2014

View full text Add to dashboard Cite

“…In adults, a test of preference for investigating a novel conspecific versus an inanimate object showed that adult male and female FLX-exposed rats had less of a preference for the conspecific [52], which could reflect reduced social motivation. Sexual behaviours in male rats are disrupted or decreased by postnatal FLX, administered either directly to the pup or indirectly via the dam's milk [26,52], but not following exposure throughout pregnancy and lactation in mice, though this treatment was found to reduce sexual motivation, as assessed by preference for investigating a receptive female over an adult male [57]. Other studies have found no effect on male sexual behaviour or motivation following prenatal or combined prenatal and postnatal exposure.…”

Section: Long-term Behavioural Outcomesmentioning

confidence: 99%

Long-Term Outcomes of Developmental Exposure to Fluoxetine: A Review of the Animal Literature

2013

View full text Add to dashboard Cite

During and following pregnancy, women are at high risk of experiencing depression, for which fluoxetine (FLX; brand names Prozac, Sarafem, Rapiflux) is the most commonly prescribed treatment. An estimated 1.4-2.1% of pregnant women use this medication, which inhibits the reuptake of serotonin and thereby increases serotonergic activity at the synapse. Serotonin acts as a cue guiding numerous neurodevelopmental processes, and changes in the concentration of serotonin can disrupt normal in utero brain development and organization in humans and other animals, thus providing a mechanism by which maternal intake of FLX might alter neural development and ultimately behaviour. Despite this possibility, long-term alterations of behaviour and the brain have not been well studied in individuals exposed to FLX during pregnancy or soon after birth, perhaps because conducting such studies beyond infancy presents significant challenges. To remedy this problem, many researchers have turned to modelling the effects of developmental FLX exposure in non-human animals, primarily rodents. The body of literature on this topic has expanded considerably over the past several years, yet a comprehensive review is lacking. In order to fill this gap, we have summarized the findings of those studies describing the long-term behavioural and neurophysiological effects of FLX exposure in non-human animals in early development. We also discuss methodological considerations and common shortcomings of research in this area. The precise nature of the long-term effects of developmental FLX exposure remains difficult to specify, as these effects appear to be highly variable and dependent on numerous factors. Overall, however, it is clear that early FLX exposure in non-human animals can alter the development of the brain in ways that are relevant to behaviour in adulthood, decreasing exploration and social interaction, and in some cases altering anxiety- and depression-like behaviours.

show abstract

Maternal exposure to the antidepressant fluoxetine impairs sexual motivation in adult male mice

Cited by 46 publications

References 32 publications

Perinatal selective serotonin reuptake inhibitor (SSRI) effects on body weight at birth and beyond: A review of animal and human studies

Perinatal selective serotonin reuptake inhibitor (SSRI) effects on body weight at birth and beyond: A review of animal and human studies

Prenatal Antidepressant Exposure: Clinical and Preclinical Findings

Long-Term Outcomes of Developmental Exposure to Fluoxetine: A Review of the Animal Literature

Contact Info

Product

Resources

About